Grace Therapeutics, Inc. Stock Analysis & AI Score
Grace Therapeutics, Inc. (GRCE) has an ST Score of 61.4 (B), driven by its Financial Strength (A+) and held back by its Momentum (C+). Analysts rate it Buy with a $4.00 price target (+85.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Grace Therapeutics, Inc. (GRCE) has an ST Score of 61.4 (B), driven by its Financial Strength (A+) and held back by its Momentum (C+). Analysts rate it Buy with a $4.00 price target (+85.2% upside).
- Strongest
- Financial StrengthA+
- Weakest
- MomentumC+
All factor grades
- Financial StrengthA+
- GrowthA
- ForecastA-
- ValuationB-
- ProfitabilityC+
- MomentumC+
- Piotroski2/9
Contact
GRCE stock: frequently asked questions
What is GRCE's ST Score?
Grace Therapeutics, Inc. (GRCE) has an ST Score of 61.4 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is GRCE a buy, hold, or sell?
Analysts rate GRCE a Buy, with a price target of $4.00 (+85.2% vs the current price). Our ST Score grades it B (61.4/100). The ST Score is a data-driven signal, not a recommendation.
What are GRCE's factor grades?
Valuation B-, Profitability C+, Financial Strength A+, Momentum C+, Growth A, Forecast A-.
What is GRCE's valuation grade?
Grace Therapeutics, Inc. (GRCE) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is GRCE's growth grade?
Grace Therapeutics, Inc. (GRCE) earns a growth grade of A, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is GRCE's profitability grade?
Grace Therapeutics, Inc. (GRCE) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is GRCE's financial strength grade?
Grace Therapeutics, Inc. (GRCE) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for GRCE?
The average analyst price target for Grace Therapeutics, Inc. (GRCE) is $4.00 from 2 analysts, which is +85.2% versus the recent price of $2.16.
What is GRCE's Piotroski score?
Grace Therapeutics, Inc. (GRCE) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.